Table Of Contents
1 Introduction 58
1.1 Overview Of Global Injectable Drug Delivery Market 58
1.2 Currency And Pricing 59
1.3 Limitation 59
1.4 Markets Covered 60
2 Market Segmentation 63
2.1 Markets Covered 63
2.2 Geographic Scope 64
2.3 Years Considered For The Study 65
2.4 Currency And Pricing 65
2.5 Research Methodology 66
2.6 Primary Interviews With Key Opinion Leaders 69
2.7 Secondary Sources 70
2.8 Assumptions 70
3 Market Overview 71
3.1 Drivers 73
3.1.1 Rising Cases Of Chronic Diseases 73
3.1.2 Rising Demand Of Self-Injection Devices 75
3.1.3 Growth Of Biologics Market 75
3.1.4 Technological Advancements And Innovations In Drug Delivery Market 76
3.2 Restraints 77
3.2.1 Needlestick Injuries And Infections 77
3.2.2 High Cost Of Development 78
3.2.3 Strict Regulatory Framework 79
3.3 Opportunity 80
3.3.1 Increasing Demand For Generic And Biosimilar Drugs 80
3.3.1.1 Generics 80
3.3.1.2 Biosimilars 80
3.3.2 Increasing Demand For Contraceptive Injectables 81
3.3.3 Increasing Demand For Self-Administration Of Drugs 82
3.4 Challenges 83
3.4.1 Alternative Route Of Drug Administration 83
3.4.2 Product Recall 84
3.4.3 Stability Of Products 84
3.4.4 Sterility Of Injections 85
4 Executive Summary 86
5 Premium Insights 88
?
6 Global Injectable Drug Delivery Market, By Type 91
6.1 Overview 92
6.2 Injectable Drug Delivery Devices 93
6.2.1 Conventional Injection Devices 94
6.2.1.1 Conventional Injection Devices, By Material 94
6.2.1.1.1 Glass 95
6.2.1.1.2 Plastic 95
6.2.1.2 Conventional Injection Devices, By Product 96
6.2.1.2.1 Fillable Syringes 96
6.2.1.2.2 Prefilled Syringes 96
6.2.1.3 Conventional Injection Devices, By Usability 98
6.2.1.3.1 Reusable Syringes 98
6.2.1.3.2 Disposable Syringes 98
6.2.2 Self Injection Devices 99
6.2.2.1 Needle Free Injectors (Nfi) 100
6.2.2.2 Needle Free Injectors, By Product 101
6.2.2.2.1 Fillable Needle-Free Injectors 101
6.2.2.2.2 Prefilled Needle-Free Injectors 101
6.2.2.3 Needle Free Injectors, By Technology 101
6.2.2.3.1 Jet Based Needle Free Injectors; 102
6.2.2.3.2 Spring Based Needle Free Injectors; 102
6.2.2.3.3 Laser Based Needle Free Injectors; 103
6.2.2.3.4 Vibration Based Needle Free Injectors; 103
6.2.2.4 Needle Free Injectors, By Usability 103
6.2.2.4.1 Reusable Needle-Free Injectors 103
6.2.2.4.2 Disposable Needle-Free Injectors 104
6.2.2.5 Auto Injectors 105
6.2.2.6 Auto Injectors, By Product 105
6.2.2.6.1 Fillable Auto Injectors 105
6.2.2.6.2 Pre-Filled Autoinjectors 105
6.2.2.7 Auto Injectors, By Technology 106
6.2.2.7.1 Automated Auto Injectors 106
6.2.2.7.2 Manual Auto Injectors 106
6.2.2.8 Auto Injectors, By Design 107
6.2.2.8.1 Standardized Auto Injectors 107
6.2.2.8.2 Automated Autoinjectors 107
6.2.2.9 Auto Injectors, By Usability 108
6.2.2.9.1 Reusable Autoinjectors 108
6.2.2.9.2 Disposable Autoinjectors 108
6.2.2.10 Pen Injectors 109
?
6.2.2.11 Pen Injectors, By Product 109
6.2.2.11.1 Single Chambered Pen Injectors 110
6.2.2.11.2 Dual Chambered Pen Injectors 110
6.2.2.12 Pen Injectors, By Design 111
6.2.2.12.1 Standard Pen Injectors 111
6.2.2.12.2 Customized Pen Injectors 111
6.2.2.13 Pen Injectors, By Usability 111
6.2.2.13.1 Reusable Pen Injectors 111
6.2.2.13.2 Disposable Pen Injectors 112
6.2.2.14 Wearable Injectors 113
6.2.2.14.1 Other Devices 113
6.3 Injectable Drug Delivery Formulation 114
6.3.1 Conventional Drug Delivery Formulations 114
6.3.1.1 Solutions 115
6.3.1.2 Reconstituted/Lyophilized Formulations 115
6.3.1.3 Suspensions 116
6.3.1.4 Emulsions 117
6.3.2 Novel Drug Delivery Formulations 118
6.3.2.1 Colloidal Dispersions 120
6.3.2.1.1 Niosomes 121
6.3.2.1.2 Liposomes 121
6.3.2.1.3 Polymeric Mixed Micelles 122
6.3.2.1.4 Nanoparticles 123
6.3.2.1.5 Nanosuspensions 124
6.3.2.1.6 Nanoemulsions/Microemulsions 124
6.3.2.1.7 Solid Lipid Nanoparticles 125
6.3.2.2 Microparticles 126
6.3.2.2.1 Microspheres 126
6.3.2.2.2 Microcapsules 127
6.3.2.3 Long Acting Injection Formulation 128
7 Global Injectable Drug Delivery Market, By Application 130
7.1 Overview 131
7.2 Global Injectable Drug Delivery Market, By Application 132
7.3 Hormonal Disorders 133
7.3.1 Injectable Drugs For Diabetes 133
7.3.2 Injectable Drugs For Anemia 134
7.3.3 Injectable Drugs For Reproductive Health Disease 134
7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 136
7.3.5 Injectable Drugs For Osteoporosis 136
7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 137
?
7.4 Oncology 139
7.5 Autoimmune Diseases 141
7.5.1 Injectable Drugs For Rheumatoid Arthritis 141
7.5.2 Injectable Drugs For Multiple Sclerosis 142
7.5.3 Injectable Drugs For Crohn?S Diseases 143
7.5.4 Injectable Drugs For Psoriasis 144
7.5.5 Injectable Drugs For Other Autoimmune Diseases 145
7.6 Orphan Disease 146
7.7 Other Applications 148
7.7.1 Injectable Drugs For Pain Management 148
7.7.2 Injectable Drugs For Allergy Treatment 149
7.7.3 Injectable Drugs For Aesthetic Treatments 150
7.7.4 Injectable Drugs For Hepatitis C 151
7.7.5 Injectable Drugs For Hemophilia 152
8 Global Injectable Drug Delivery Market, By Usage Pattern 154
8.1 Overview 155
8.2 Curative Care 156
8.3 Immunizations 157
8.4 Other Usage Pattern 157
9 Global Injectable Drug Delivery Market, By Mode Of Administration 159
9.1 Overview 160
9.2 Skin 161
9.3 Circulatory/ Muskoskeletal 161
9.4 Organs 162
9.5 Central Nervous System 162
10 Global Injectable Drug Delivery Market, By End User 164
10.1 Overview 165
10.2 Hospitals And Clinics 167
10.3 Home Healthcare Settings 167
10.4 Research Laboratories 167
10.5 Pharmaceutical And Biotechnological Companies 168
10.6 Other End Users 169
11 Global Injectable Drug Delivery Market, By Distribution Channel 170
11.1 Overview 171
11.1.1 Hospital Pharmacy 172
11.1.2 Pharmacy Stores 172
11.1.3 Direct Tender 172
11.1.4 Online Pharmacy 172
?
12 Global Injectable Drug Dilivery Market By Geography 174
12.1 Overview 174
12.2 North America 176
12.2.1 U.S. 194
12.2.2 Canada 209
12.2.3 Mexico 225
12.3 Europe 241
12.3.1 Germany 259
12.3.2 France 274
12.3.3 U.K. 291
12.3.4 Italy 306
12.3.5 Switzerland 322
12.3.6 Spain 338
12.3.7 Netherland 354
12.3.8 Russia 371
12.3.9 Turkey 385
12.3.10 Belgium 400
12.3.11 Rest Of Europe 417
12.4 Asia-Pacific 418
12.4.1 Japan 436
12.4.2 China 452
12.4.3 India 467
12.4.4 South Korea 482
12.4.5 Australia 497
12.4.6 Thailand 512
12.4.7 Malaysia Injectable Drug Delivery Market 528
12.4.8 Singapore 543
12.4.9 Indonesia 558
12.4.10 Phillippines 573
12.4.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 588
12.5 South America 589
12.5.1 Brazil 606
12.5.2 Rest Of South Africa 622
12.6 Middle East & Africa 623
12.6.1 South Africa Injectable Drug Delivery Market 640
12.6.2 Rest Of Middle East& Africa Injectable Drug Delivery Market 656
13 Global Injectable Drug Delivery Market, Company Share 657
13.1 Company Share Analysis; Global 657
?
14 Company Profiles 658
14.1 Becton, Dickinson And Company 658
14.1.1 Company Overview 658
14.1.1.1 Drivers Explained 659
14.1.1.2 Weaknesses Explained 659
14.1.1.3 Oppurtunities Explained 659
14.1.1.4 Threats Explained 660
14.1.2 Becton, Dickinson And Company; Revenue Analysis 660
14.1.3 Product Portfolio 662
14.1.4 Recent Developments 663
14.2 Pfizer 665
14.2.1 Company Overview 665
14.2.1.1 Drivers Explained 666
14.2.1.2 Weaknesses Explained 666
14.2.1.3 Oppurtunities Explained 667
14.2.1.4 Threats Explained 668
14.2.2 Pfizer, Inc.; Revenue Analysis 668
14.2.3 Product Portfolio 669
14.2.4 Recent Developments 671
14.3 Baxter International, Inc. 674
14.3.1 Company Overview 674
14.3.1.1 Drivers Explained 675
14.3.1.2 Weaknesses Explained 676
14.3.1.3 Oppurtunities Explained 676
14.3.1.4 Threats Explained 676
14.3.2 Baxter International; Revenue Analysis 677
14.3.3 Product Portfolio 679
14.3.4 Recent Developments 679
14.4 Gerresheimer Ag 681
14.4.1 Company Overview 681
14.4.2 Gerresheimer Ag; Revenue Analysis 681
14.4.3 Product Portfolio 682
14.4.4 Recent Developments 682
14.5 Schott Ag Inc. 683
14.5.1 Company Overview 683
14.5.2 Schott Ag Inc; Revenue Analysis 683
14.5.3 Product Portfolio 684
14.5.4 Recent Developments 684
?
14.6 Alkermes Inc. 686
14.6.1 Company Overview 686
14.6.2 Alkermes Inc.; Revenue Analysis 686
14.6.3 Product Portfolio 686
14.6.4 Recent Developments 687
14.7 Antares Pharma 689
14.7.1 Company Overview 689
14.7.2 Antares Pharma; Revenue Analysis 689
14.7.3 Product Portfolio 690
14.7.4 Recent Developments 691
14.8 Bespak (Subsidiary Of Consort Medical Company) 692
14.8.1 Company Overview 692
14.8.2 Bespak (Subsidiary Of Consort Medical Company); Revenue Analysis 692
14.8.3 Product Portfolio 693
14.8.4 Recent Developments 693
14.9 Elcam Medical 695
14.9.1 Company Overview 695
14.9.2 Elcam Medical; Company Snapshot 695
14.9.3 Product Portfolio 696
14.9.4 Recent Developments 696
14.10 Eli Lilly And Company 697
14.10.1 Company Overview 697
14.10.1.1 Drivers Explained 698
14.10.1.2 Weaknesses Explained 698
14.10.1.3 Oppurtunities Explained 699
14.10.1.4 Threats Explained 700
14.10.2 Eli Lilly And Company ; Revenue Analysis 700
14.10.3 Product Portfolio 702
14.10.4 Recent Developments 703
14.11 Haselmeier 705
14.11.1 Company Overview 705
14.11.2 Haselmeier; Company Snapshot 705
14.11.3 Product Portfolio 705
14.11.4 Recent Developments 706
14.12 Mylan N.V. 707
14.12.1 Company Overview 707
14.12.2 Mylan N.V.; Revenue Analysis 707
14.12.3 Product Portfolio 708
14.12.4 Recent Developments 708
?
14.13 Novo Nordisk 711
14.13.1 Company Overview 711
14.13.2 Novo Nordisk; Revenue Analysis 711
14.13.3 Product Portfolio 712
14.13.4 Recent Developments 713
14.14 Owen Mumford Ltd 715
14.14.1 Company Overview 715
14.14.2 Owen Mumford Ltd; Company Snapshot 715
14.14.3 Product Portfolio 716
14.14.4 Recent Developments 716
14.15 Sandoz International Gmbh 718
14.15.1 Company Overview 718
14.15.2 Sandoz International Gmbh; Revenue Analysis 718
14.15.3 Product Portfolio 718
14.15.4 Recent Developments 719
14.16 Sanofi 720
14.16.1 Company Overview 720
14.16.2 Sanofi; Revenue Analysis 720
14.16.3 Product Portfolio 721
14.16.4 Recent Developments 721
14.17 Terumo Corporation 723
14.17.1 Company Overview 723
14.17.2 Terumo Corporation; Revenue Analysis 723
14.17.3 Product Portfolio 723
14.17.4 Recent Developments 724
14.18 Teva Pharmaceutical 726
14.18.1 Company Overview 726
14.18.1.1 Drivers Explained 727
14.18.1.2 Weaknesses Explained 727
14.18.1.3 Oppurtunities Explained 727
14.18.1.4 Threats Explained 728
14.18.2 Teva Pharmaceutical; Revenue Analysis 729
14.18.3 Product Portfolio 731
14.18.4 Recent Developments 732
14.19 West Pharmaceutical Services, Inc 735
14.19.1 Company Overview 735
14.19.2 West Pharmaceutical Services, Inc; Revenue Analysis 735
14.19.3 Product Portfolio 736
14.19.4 Recent Developments 737
?
14.20 Ypsomed Holding Ag 738
14.20.1 Company Overview 738
14.20.2 Ypsomed Holding Ag; Revenue Analysis 738
14.20.3 Product Portfolio 738
14.20.4 Recent Developments 739
15 Related Reports 741